Full Papers
Validation of simplified scoring systems for assessing cutaneous disease activity in dermatomyositis
N. Pongtarakulpanit1, A. Bishnoi2, T. Chandra3, S. Dzanko4, E. Gkiaouraki5, S. Keret6, R. Lomanto Silva7, S. Sriram8, D. Saygin9, V.M. Liarski10, D.P. Ascherman11, S. Moghadam-Kia12, C.V. Oddis13, R. Aggarwal14
- Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; and Division of Allergy, Immunology and Rheumatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
- Department of Dermatology, UPMC, Pittsburgh, PA, USA.
- Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
- Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
- Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
- Rheumatology, Bnai-Zion Medical Center, Faculty of Medicine, Technion, Haifa, Israel.
- Department of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, USA.
- Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
- Rush University Medical Center, Division of Rheumatology, Chicago, IL, USA.
- Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
- Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
- Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
- Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
- Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. aggarwalr@upmc.edu
CER19017
Full Papers
Free to view
(click on article PDF icon to read the article)
PMID: 41678167 [PubMed]
Received: 18/06/2025
Accepted : 12/01/2026
In Press: 12/02/2026
Abstract
OBJECTIVES:
The Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) is a standard clinician-scored outcome measure for dermatomyositis (DM), but requires expertise and training. We aimed to validate simplified versions of the CDASI activity score.
METHODS:
Adult DM patients were prospectively enrolled with two clinic visits ≥2 months apart. Two rheumatologists independently assessed patients using the CDASI activity score (range 0–100) and the cutaneous visual analogue scale of the Myositis Disease Activity Assessment Tool (MDAAT cutaneous VAS). Additionally, patients completed the Skindex questionnaire. Four simplifications (sCDASI) were derived: (1) sCDASI-1 (range 0–66), simplified erythema to absent/present (0–1); (2) sCDASI-2 (range 0–36), simplified erythema and exclusion of scale scoring; (3) sCDASI-3 (range 0–20), simplified erythema, exclusion of scale and ulcer scoring; (4) sCDASI-4, (range 0–50), simplification of all parameters to absent/present.
RESULTS:
Twenty-seven DM patients (81.5% female, 96.3% White, median age 50.0) were included. Median CDASI activity was 4.5 (IQR 1.0–12.0). All sCDASI scores correlated strongly with the full CDASI (Spearman ρ=0.97–0.98), MDAAT cutaneous VAS (Spearman ρ=0.94), and Skindex (Spearman ρ=0.82–0.83), indicating good convergent validity. Inter-rater reliability for all simplifications was high, as indicated by strong correlations between assessors. The changes from baseline in simplified CDASI scores correlated strongly with the changes in full CDASI scores and MDAAT cutaneous VAS, demonstrating good responsiveness.
CONCLUSIONS:
Simplified CDASI scorings demonstrated preliminary evidence of favourable validity, reliability, and responsiveness in the longitudinal evaluation of rashes in DM patients.
